Retatrutide vs. Mounjaro: Two Drugs, One Company, Different Targets

An Unusual Portfolio Question

Eli Lilly finds itself in a position few pharmaceutical companies have occupied: developing two distinct incretin-based therapies for overlapping indications in obesity and type 2 diabetes. Tirzepatide (marketed as Mounjaro for diabetes and Zepbound for obesity) is a dual GIP/GLP-1 receptor agonist already on the market. Retatrutide (LY3437943) is a triple GIP/GLP-1/glucagon receptor agonist still in Phase 3 development. Understanding how these two molecules differ — and how Lilly might position them — requires examining their pharmacology, clinical data, and the broader strategic landscape.

Dual vs. Triple Agonism

Tirzepatide activates two receptors: GIP and GLP-1. This dual mechanism produced unprecedented weight loss in the SURMOUNT trials, with mean reductions of up to 22.5% at 72 weeks in adults with obesity.

Retatrutide adds a third target: the glucagon receptor. Preclinical work published by Coskun et al. demonstrated that this triple agonist approach in animal models produced greater weight loss and metabolic improvements than dual agonism alone. The glucagon component is believed to increase energy expenditure primarily through hepatic lipid oxidation and thermogenic pathways, providing a mechanistically distinct contribution beyond appetite suppression and insulin sensitization.

In Phase 2 human data, retatrutide at the 12 mg dose showed 24.2% mean body weight loss at 48 weeks — a shorter treatment duration than the 72-week SURMOUNT results, making direct numerical comparison difficult but suggesting a potentially steeper efficacy trajectory.

Different Development Timelines

Tirzepatide is years ahead in development. It received FDA approval for type 2 diabetes in 2022 and for chronic weight management in 2023. Its safety and efficacy profile is supported by extensive Phase 3 data across multiple patient populations, including those with heart failure, obstructive sleep apnea, and type 2 diabetes.

Retatrutide is currently in Phase 3 trials. The TRIUMPH program is evaluating the drug across several indications. Assuming positive results, regulatory submissions are not expected until data readouts are complete, placing potential approval several years behind tirzepatide.

Potential Clinical Differentiation

If both drugs ultimately reach the market for obesity, how might they be differentiated? Several possibilities exist:

• Efficacy magnitude: If Phase 3 data confirm the Phase 2 signal, retatrutide may offer greater absolute weight loss than tirzepatide. For patients with severe obesity (BMI > 40) or those who have not achieved target weight loss on existing therapies, a more potent option could fill a clinical need.
• Metabolic effects: The glucagon receptor component may confer distinct benefits on hepatic steatosis and lipid metabolism. Early data suggest retatrutide produces significant reductions in liver fat, which could position it favorably for patients with metabolic dysfunction-associated steatotic liver disease (MASLD).
• Tolerability profile: Whether the addition of glucagon agonism alters the side effect profile in clinically meaningful ways remains to be fully characterized in Phase 3. Theoretically, glucagon receptor activation could raise concerns about glycemic effects, though this has not been a prominent issue in Phase 2 data, likely due to the counterbalancing effects of GLP-1 and GIP agonism.

Portfolio Strategy

From a commercial perspective, Lilly’s dual-product approach may not be as redundant as it appears. The obesity pharmacotherapy market is expected to be large enough to support multiple agents, and different patients may respond differently to dual versus triple agonism. A portfolio approach also hedges development risk — if one molecule encounters unexpected safety signals, the other provides continuity.

There is also the possibility of indication-specific positioning. Tirzepatide may become the established first-line incretin therapy, while retatrutide could be positioned for patients requiring more intensive intervention, or for specific comorbidities where the glucagon component offers additional benefit.

Looking Ahead

The relationship between tirzepatide and retatrutide within Lilly’s pipeline will become clearer as Phase 3 data emerge. For now, the two molecules represent an iterative advancement in incretin pharmacology — from dual to triple agonism — with the clinical significance of that third receptor target being the central question that ongoing trials must answer.